openPR Logo
Press release

Hereditary Angioedema Market Research Report 2032

02-21-2023 08:22 AM CET | Health & Medicine

Press release from: DelveInsight Business Research

Hereditary Angioedema Market

Hereditary Angioedema Market

DelveInsight's "Hereditary Angioedema Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the Hereditary Angioedema, historical and forecasted epidemiology as well as the Hereditary Angioedema market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Hereditary Angioedema (HAE) is a rare genetic disorder caused by the deficiency in functional C1 inhibitor (C1INH) that results in recurrent attacks of localized subcutaneous or mucosal edema, most commonly affecting the skin, intestines, upper respiratory tract, and oropharynx.

Get FREE sample copy at:
https://www.delveinsight.com/sample-request/hereditary-angioedema-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

HAE is a heterogeneous disease with complex pathophysiology that involves several pathways resulting in the increased production of bradykinin with mutations of multiple molecules in genetic etiology. These could include the Kallikrein gene mutations; Bradykinin gene or its receptor mutations; Kininase 1 gene mutations and loss of function and mutations in gene encoding aminopeptidase and ACE enzymes.

It is classified into three types based on genetic defects such as type I HAE with low levels of C1-INH in the body, type II with poorly functioning C1-INH, or the recently identified types of HAE with normal functioning C1-INH (formerly known as type III HAE). Identification of the novel polymorphisms in several genes leading to modification in the clinical phenotype of HAE is a relatively recent phenomenon. The clinical features of HAE are recurrent and unpredictable spontaneous edema attacks. Traumas, infections, stress, or medical procedures are potential triggers for HAE attacks, and occasionally, angioedema could be associated with prodromal signs, including erythema marginatum.

Get FREE sample copy at:
https://www.delveinsight.com/report-store/hereditary-angioedema-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

The Hereditary Angioedema market report also covers emerging drugs, current treatment practices, Hereditary Angioedema market share of the individual therapies, current and forecasted Hereditary Angioedema Market Size from 2019 to 2032 segmented by seven major markets.

The report provides a detailed current Hereditary Angioedema treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Hereditary Angioedema Market Key Facts
• Total diagnosed prevalent population of Hereditary Angioedema (HAE) in 7MM countries was estimated to be 14,435 cases in 2017.
• Among the European countries, France had the highest prevalent population of 1,346 cases, followed by the UK which had prevalent population of 1,301 in 2017.
• HAE in the US has been observed with the maximum number of diagnosed cases in the age-group 17 to below 65 years, followed by those who belong to the age-group 12 to less than 17 years.
• Among the European 5 countries, Spain had the lowest prevalent population with 537 cases in 2017.

Key Benefits of Hereditary Angioedema Market Report
• Hereditary Angioedema market report provides an in-depth analysis of Hereditary Angioedema Market Size, Share, Trend, Epidemiology and Market Forecast till 2032, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
• The Hereditary Angioedema market report will help in developing business strategies by understanding the Hereditary Angioedema Market trends & developments, key players and future market competition that will shape and drive the Hereditary Angioedema market in the upcoming years.
• The Hereditary Angioedema market report covers Hereditary Angioedema current treatment practices, emerging drugs, market share of the individual therapies in 7MM.
• The report provides a detailed assessment of the Hereditary Angioedema market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.

Get FREE sample copy at:
https://www.delveinsight.com/sample-request/hereditary-angioedema-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Hereditary Angioedema Market
The landscape of therapeutic options for patients with HAE has changed dramatically in the last two decades. Ongoing research promises even greater change in the foreseeable future. Given the economic and psychosocial burdens for patients living with angioedema, effective therapies with novel mechanisms will offer more choices for patients and physicians, as well as provide greater flexibility in routes of administration. Owing to the launch of upcoming therapies, market size shall increase during forecast period (2019-2032).

The Hereditary Angioedema market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Hereditary Angioedema market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.

The report gives a thorough detail of Hereditary Angioedema market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.

Get FREE sample copy at:
https://www.delveinsight.com/sample-request/hereditary-angioedema-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Hereditary Angioedema Epidemiology
The Hereditary Angioedema epidemiology section covers insights about historical and current Hereditary Angioedema patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Hereditary Angioedema Drugs Uptake and Key Market Players
The Hereditary Angioedema Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hereditary Angioedema market or expected to get launched in the market during the study period. The analysis covers Hereditary Angioedema market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report's Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Companies are focusing on executing a successful launch that meets the urgent demand for a once-daily oral therapy that will allow HAE patients to live a more normal life. An orally delivered, small molecule offers the opportunity to improve treatment for the disease by making it more convenient for patients to take therapies.

Some of the key players in the Hereditary Angioedema Market includes:
• BioCryst Pharmaceuticals
• Ionis Pharmaceuticals
• KalVista Pharmaceuticals
• CSL Behring
• Takeda
• Shire
• Pharming Group
• And many others.

Get FREE sample copy at:
https://www.delveinsight.com/sample-request/hereditary-angioedema-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Hereditary Angioedema Drugs Covered
• BCX7353
• IONIS-PKK-LRx
• KVD900
• CSL312
• And many others.

Table of Content
1. Key Insights
2. Executive Summary
3. Hereditary Angioedema Competitive Intelligence Analysis
4. Hereditary Angioedema Market Overview at a Glance
5. Hereditary Angioedema Disease Background and Overview
6. Hereditary Angioedema Patient Journey
7. Hereditary Angioedema Epidemiology and Patient Population
8. Hereditary Angioedema Treatment Algorithm, Current Treatment, and Medical Practices
9. Hereditary Angioedema Unmet Needs
10. Key Endpoints of Hereditary Angioedema Treatment
11. Hereditary Angioedema Marketed Products
12. Hereditary Angioedema Emerging Therapies
13. Hereditary Angioedema Seven Major Market Analysis
14. Attribute Analysis
15. Hereditary Angioedema Market Outlook (7 major markets)
16. Hereditary Angioedema Access and Reimbursement Overview
17. KOL Views on the Hereditary Angioedema Market.
18. Hereditary Angioedema Market Drivers
19. Hereditary Angioedema Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: info@delveinsight.com
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hereditary Angioedema Market Research Report 2032 here

News-ID: 2940281 • Views:

More Releases from DelveInsight Business Research

Immune Checkpoint Inhibitors Market Outlook 2034: Competitive Landscape, Pipeline Advancements, and Market Forecast Across the 7MM by DelveInsight
Immune Checkpoint Inhibitors Market Outlook 2034: Competitive Landscape, Pipelin …
DelveInsight's latest report, "Immune Checkpoint Inhibitors Market Forecast (2020-2034)", provides an in-depth analysis of one of the most transformative areas in oncology. According to DelveInsight estimates, the Immune Checkpoint Inhibitors (ICI) market is expected to grow at a decent CAGR throughout the forecast period, driven by the rising global burden of cancer, advances in immuno-oncology, increasing healthcare expenditures, and the anticipated approval of novel ICIs across the 7MM [the United
HPK1 Inhibitors Market Outlook 2034: Competitive Landscape, Pipeline Advancements, and Market Forecast Across the 7MM by DelveInsight
HPK1 Inhibitors Market Outlook 2034: Competitive Landscape, Pipeline Advancement …
(Albany, USA, September 2025) - DelveInsight has released its latest report, "HPK1 Inhibitor Competitive Landscape And Market Forecast - 2034," delivering an in-depth analysis of the rapidly evolving HPK1 inhibitor market. The report offers a comprehensive overview of the epidemiology, drug uptake, treatment landscape, competitive intelligence, and market dynamics shaping the outlook of HPK1 inhibitors across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan. To know
Focal Adhesion Kinase (FAK) Inhibitors Market Outlook 2034: Scientific Advances, Clinical Developments, and Emerging Opportunities by DelveInsight
Focal Adhesion Kinase (FAK) Inhibitors Market Outlook 2034: Scientific Advances, …
(Albany, USA, September 2025) - Focal Adhesion Kinase (FAK), also known as PTK2, has emerged as one of the most promising molecular targets in oncology research and therapy development. Encoded by the PTK2 gene, FAK is a non-receptor tyrosine kinase critically involved in signal transduction mediated by growth factor receptors and integrins. Increasing evidence shows that overexpression of FAK is directly associated with tumor progression, therapy resistance, and poor clinical
Thyroid Eye Disease Market Set for Robust Expansion Through 2034, DelveInsight Reports
Thyroid Eye Disease Market Set for Robust Expansion Through 2034, DelveInsight R …
DelveInsight's "Thyroid Eye Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Thyroid Eye Disease, historical and forecasted epidemiology as well as the Thyroid Eye Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Thyroid Eye Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Thyroid Eye Disease

All 5 Releases


More Releases for Hereditary

Hereditary Angioedema Market: An In-Depth Analysis
In 2024, the market for Hereditary Angioedema Market was valued at USD 3.1 billion. It is anticipated to grow to USD 5.9 billion by 2033, with a CAGR of 6.82% over the period 2026-2033. Hereditary Angioedema Market Overview The global hereditary angioedema therapeutics market is experiencing significant expansion, driven by increasing awareness, improved diagnostic capabilities, and the introduction of novel treatment options. Advances in genetic research have enabled early and accurate
Leber Hereditary Optic Neuropathy Treatment Market
Introduction Leber Hereditary Optic Neuropathy (LHON) is a genetic condition that leads to severe vision loss, primarily affecting young adults. This disorder is caused by mutations in mitochondrial DNA, which impairs the function of retinal ganglion cells. As awareness of LHON has grown, so too has the focus on its treatment options. The LHON treatment market is evolving rapidly, driven by advancements in genetic therapies, pharmaceuticals, and supportive care strategies. This
Hereditary Hemochromatosis Market - Redefining Care, Inspiring Hope: Hereditary …
Newark, New Castle, USA: The "Hereditary Hemochromatosis Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors. Hereditary Hemochromatosis Market: https://www.growthplusreports.com/report/hereditary-hemochromatosis-market/8793 This latest report researches the industry structure, sales, revenue,
Hereditary Angioedema - Drug Pipeline Landscape, 2022
Global Hereditary Angioedema Market report from Global Insight Services is the single authoritative source of intelligence on hereditary angioedema market. The report will provide you with analysis of impact of latest market disruptions such as Russia-Ukraine war and Covid-19 on the market. Report provides qualitative analysis of the market using various frameworks such as Porters' and PESTLE analysis. Report includes in-depth segmentation and market size data by categories, product types,
Hereditary Angioedema - Drug Pipeline Landscape, 2022
Hereditary Angioedema is an infrequent inherited disease that causes substantial swelling in various body tissues, such as the abdomen or face caused by a low level or improper function of a protein called the C1 inhibitor. There are three types of hereditary angioedema namely type I, II, and III. Hereditary Angioedema is mainly caused by a low level or improper function of a protein called the C1 inhibitor. Read more about Hereditary
Hereditary Testing Market Size – Forecasts to 2026
The results analyzed by GME showed that the Global Hereditary Testing Market will grow with a CAGR value of 7.1 percent, to hit xx billion USD by 2026. During the forecast timeframe, growth is expected to be driven by growing expenditure on R&D activities and the rising incidence of chronic diseases worldwide. The development may be attributed to the advancement of genetic testing services and the growing demand for personalized